The Latest Breaking News from CSTL

Castle Biosciences Adds Mental Health Testing Solutions Via AltheaDx Acquisition

Castle Biosciences Inc (NASDAQ: CSTL) has agreed to acquire AltheaDx Inc, a commercial-stage molecular diagnostics company, 

Benzinga · Apr 5, 2022

Castle Biosciences's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Castle Biosciences (NASDAQ:CSTL) posted sales of $25.04 million. Earnings were up 45.47%, but Castle Biosciences still reported an overall loss of $6.43 million.

Benzinga · Mar 2, 2022